101 related articles for article (PubMed ID: 7208336)
1. [Fenofibrate: chemical development and differences with clofibrate (author's transl)].
Boucherle A
Nouv Presse Med; 1980 Dec; 9(49):3721-3. PubMed ID: 7208336
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacology of fenofibrate (author's transl)].
Kritchevsky D
Nouv Presse Med; 1980 Dec; 9(49):3769-73. PubMed ID: 7208345
[TBL] [Abstract][Full Text] [Related]
3. [Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].
Barnard SD; Molello JA; Caldwell WJ; Lebeau JE
Nouv Presse Med; 1980 Oct; 9(40):3005-7. PubMed ID: 7443440
[TBL] [Abstract][Full Text] [Related]
4. [Amino acid derivatives of 2-(p-chlorophenoxy)-2-methylpropionic acid as compounds with potential antilipemic agents. II. Preparation of methyl esters of N-[2-(p-chlorophenoxy)-2-methylpropionyl] amino acids].
Kwapiszewski W; Borkowski L
Acta Pol Pharm; 1987; 44(2):121-31. PubMed ID: 3434313
[No Abstract] [Full Text] [Related]
5. [Chemistry of phenoxyacetic acid esters of oxyalkyltheophyllines and 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methyl-propionate] (etofylline clofibrate), a novel antilipaemic agent (author's transl)].
Metz G; Specker M
Arzneimittelforschung; 1980; 30(11b):2014-9. PubMed ID: 7194051
[TBL] [Abstract][Full Text] [Related]
6. Potential hypolipidemic agents. XIV. Synthesis and plasma lipid-lowering properties of substituted biphenyls, diphenyl ethers and benzofurans related to ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate.
Bondesson G; Högberg T; Misiorny A; Stjernström NE
Acta Pharm Suec; 1976; 13(2):97-106. PubMed ID: 937013
[No Abstract] [Full Text] [Related]
7. Potential hypolipidemic agents. XVII. Synthesis and plasma lipid-lowering properties of compounds related to ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate and ethyl 2-(4-chlorophenoxy)-2-methylpropionate.
Högberg T; Bondesson G; Stjernström NE
Acta Pharm Suec; 1977; 14(2):149-60. PubMed ID: 906832
[No Abstract] [Full Text] [Related]
8. [Pharmacokinetics of fenofibrate in man (author's transl)].
Harvengt C; Desager JP
Nouv Presse Med; 1980 Dec; 9(49):3725-7. PubMed ID: 7208337
[TBL] [Abstract][Full Text] [Related]
9. Studies on antihyperlipidemic agents. I. Synthesis and hypolipidemic activities of phenoxyphenyl alkanoic acid derivatives.
Kawamatsu Y; Saraie T; Imamiya E; Nishikawa K; Hamuro Y
Arzneimittelforschung; 1980; 30(3):454-9. PubMed ID: 7387754
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological basis for the therapeutic utilisation of hypolipedmic effects of clofibrate (author's transl)].
Chevais M
Therapie; 1980; 35(1):5-22. PubMed ID: 6998038
[No Abstract] [Full Text] [Related]
11. [How does fenofibrate exert its cholesterol-lowering effect? (author's transl)].
Wülfert E
Nouv Presse Med; 1980 Dec; 9(49):3733-6. PubMed ID: 7208339
[TBL] [Abstract][Full Text] [Related]
12. [Metabolism of fenofibrate and fenofibric acid in vivo and in cultures of liver epithelial cells (author's transl)].
Dulery B; Hammami M; Chessebeuf M; Legendre M; Noly P; Padieu P; Maume BF
Nouv Presse Med; 1980 Dec; 9(49):3729-32. PubMed ID: 7208338
[TBL] [Abstract][Full Text] [Related]
13. [Hypolipidaemic agents (author's transl)].
Tillement JP; Albengres E; Choisy H; Millart H
Nouv Presse Med; 1980 Oct; 9(40):2947-50. PubMed ID: 7443428
[TBL] [Abstract][Full Text] [Related]
14. Potential hypolipidemic agents. XV Synthesis and plasma lipid-lowering properties of derivatives of 2-phenoxy-2-methylpropionic acid.
Högberg T; Bondesson G; Misiorny A; Stjernström NE
Acta Pharm Suec; 1976; 13(5-6):427-38. PubMed ID: 1020658
[No Abstract] [Full Text] [Related]
15. [Fenofibrate: animal toxicology in relation to side-effects in man (author's transl)].
Blane GF; Pinaroli F
Nouv Presse Med; 1980 Dec; 9(49):3737-46. PubMed ID: 7208340
[TBL] [Abstract][Full Text] [Related]
16. Hypolipidemic activity of some derivatives of 6H-dibenzo[b,d]pyran.
Banzatti C; Branzoli U; Lovisolo PP; Melloni P; Orsini G; Salvadori P
Arzneimittelforschung; 1984; 34(8):864-9. PubMed ID: 6541922
[TBL] [Abstract][Full Text] [Related]
17. [Influence of fenofibrate on blood platelet functions (author's transl)].
Renaud S; Dumont E; Drouin P; Debry G
Nouv Presse Med; 1980 Dec; 9(49):3763-7. PubMed ID: 7208344
[TBL] [Abstract][Full Text] [Related]
18. Ethyl 2-([5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenyl]oxy)- 2-methylpropanoate as a new potent oxyisobutyrate hypolipidaemic with unusual features.
Cozzi P; Branzoli U; Carganico G; Chiari A; Lovisolo PP; Severino D
Farmaco Sci; 1987 Mar; 42(3):205-18. PubMed ID: 3653387
[TBL] [Abstract][Full Text] [Related]
19. Antilipidemic drugs. Part 3: On the synthesis of 14C-radiolabelled isopropyl-[4'-chlorobenzoyl)-2-phenoxy-2-methyl]-propionate (LF-178).
Duc CL
Arzneimittelforschung; 1976; 26(5):894-5. PubMed ID: 989364
[TBL] [Abstract][Full Text] [Related]
20. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.
Ogata T; Miyauchi T; Sakai S; Takanashi M; Irukayama-Tomobe Y; Yamaguchi I
J Am Coll Cardiol; 2004 Apr; 43(8):1481-8. PubMed ID: 15093887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
